PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Egrifta
GHRH AnalogLast Updated: April 1, 2026
Tesamorelin (also known as Egrifta) is a prominently researched experimental compound classified strictly within the GHRH Analog framework. Operating primarily through advanced pharmacological pathways, it functions by stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue. with a documented biological half-life of roughly 0.43 hours, in preclinical investigative trials and independent academic studies, researchers utilizing Tesamorelin have documented significant, quantifiable biological outcomes, primarily focusing on visceral fat reduction, body recomposition. Typical research protocols investigate administering 1000 to 1000mcg via subq pathways 7x/week. However, it is critically important to understand that while Tesamorelin demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
Falutz et al. (JAMA): Randomized, double-blind, placebo-controlled Phase 3 trial showing 15.2% reduction in visceral adipose tissue vs. 5% increase in placebo. FDA-approved indication.
very strongFalutz et al. (J. Clin. Endocrinol. Metab.): 52-week data confirming sustained 18% visceral fat reduction with continuous therapy, with reversal upon discontinuation.
strongStanley et al. (Ann. Intern. Med.): RCT demonstrating tesamorelin reduces hepatic fat content in HIV-infected patients with abdominal fat accumulation.
strongBaker et al.: GHRH treatment (tesamorelin) shows favorable effects on executive function and verbal memory in cognitively normal and mildly impaired older adults via IGF-1 elevation.
moderatePhase 3 trial showing ~80% increase in IGF-1 levels, improved body image distress scores, and significant trunk fat reduction across multiple patient populations.
strongFDA-approved for lipodystrophy; GI side effects possible. Contraindicated in active malignancy.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
FDA-approved dose: 2mg SubQ daily. Prescription required.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Weeks 2-4
Early GH-related effects; initial fluid retention possible
Month 2-3
Measurable visceral fat reduction (avg 15% in FDA trial at this point)
Long-term
Sustained visceral fat reduction and metabolic improvement; IGF-1 normalization
| Side Effect | Incidence | Severity |
|---|---|---|
Fluid retention From Phase 3 Egrifta trial data | ~15% of users | mild |
Injection site reactions | ~12% of users | mild |
Joint pain / arthralgia | ~8% of users | mild |
Glucose elevation Monitor blood glucose; especially if pre-diabetic | ~5% of users | moderate |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Finding verified, high-purity Tesamorelin requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Tesamorelin✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Maximize fat loss while preserving or building lean muscle — the gold standard for total body transformation
PeptiDex. (2026). Tesamorelin. PeptiDex Research Platform. https://peptidex.app/library/tesamorelin
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.